---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Pathophysiology"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Pathophysiology. Topics: Upper airway collapse when anatomical collapsing forces exceed dilator muscle compensation, Endotype framework: four physiological traits that cause OSA, Endotype framework: distribution of anatomical and nonanatomical traits among patients with OSA, Endotype framework: impaired anatomy and the three nonanatomical phenotypes, and 5 further topics. 9 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/pathophysiology"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Upper airway collapse when anatomical collapsing forces exceed dilator muscle compensation

> “This will occur if the anatomical structures within or surrounding the airway produce a collapsing force that cannot be adequately compensated for by pharyngeal dilator muscles.”

Source: [Wellman et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3119134/)

<a id="topic-2.2.1.4-2"></a>

### Endotype framework: four physiological traits that cause OSA

> “In this study, we present a noninvasive method for measuring four important physiological traits causing OSA: 1) pharyngeal anatomy/collapsibility, 2) ventilatory control system gain (loop gain), 3) the ability of the upper airway to dilate/stiffen in response to an increase in ventilatory drive, and 4) arousal threshold.”
> “The measurements and model illustrate the multifactorial nature of OSA pathogenesis and how, in some individuals, small adjustments of one or another trait (which might be achievable with non-CPAP agents) could potentially treat OSA.”

Source: [Wellman et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3119134/)

<a id="topic-2.2.1.4-3"></a>

### Endotype framework: distribution of anatomical and nonanatomical traits among patients with OSA

> “A total of 36% of patients with OSA had minimal genioglossus muscle responsiveness during sleep, 37% had a low arousal threshold, and 36% had high loop gain.”
> “A total of 28% had multiple nonanatomic features.”
> “One or more nonanatomic pathophysiologic traits are present in 69% of patients with OSA.”
> “This study confirms that OSA is a heterogeneous disorder.”

Source: [Eckert et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3826282/)

<a id="topic-2.2.1.4-4"></a>

### Endotype framework: impaired anatomy and the three nonanatomical phenotypes

> “Indeed, impairment in pharyngeal anatomy can be modest and in many patients (∼20%), pharyngeal collapsibility asleep is not different to people without OSA.”
> “These include impairment in pharyngeal dilator muscle control and function during sleep, increased propensity for awakening during airway narrowing (low respiratory arousal threshold) and respiratory control instability (high loop gain).”
> “Each phenotype is a potential therapeutic target.”

Source: [Eckert (2018)](https://pubmed.ncbi.nlm.nih.gov/28110857/)

<a id="topic-2.2.1.4-5"></a>

### Endotype framework: estimating collapsibility and muscle compensation from diagnostic polysomnography

> “Here we aimed to provide a means to quantify two key contributors to OSA—pharyngeal collapsibility and compensatory muscle responsiveness—that is applicable to diagnostic polysomnography.”
> “Phenotypes of pharyngeal dysfunction in OSA are evident from spontaneous changes in ventilation and ventilatory drive during sleep, enabling noninvasive phenotyping in the clinic.”

Source: [Sands et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6019932/)

<a id="topic-2.2.1.4-6"></a>

### Pharyngeal dilator muscle control: noradrenergic withdrawal in NREM sleep and muscarinic inhibition in REM sleep

> “Some preclinical works identified the main cause of sleep-related hypotonia of the pharyngeal muscles to be the central reduction of norepinephrine from wakefulness to sleep.”
> “In addition, an inhibitory effect of acetylcholine through muscarinic receptors was found to be responsible for the REM-related hypotonia.”
> “Two key contributors are now thought to be important: sleep-related withdrawal of endogenous noradrenergic drive is a major cause of genioglossus hypotonia, particularly during non-REM (NREM) sleep (16), and active muscarinic inhibition mediates pharyngeal hypotonia, particularly during REM (17).”

Source: [Taranto-Montemurro et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6519859/)

<a id="topic-2.2.1.4-7"></a>

### Pharyngeal dilator muscle control: muscarinic and GIRK channel inhibition at the hypoglossal motor pool in REM sleep (rat study)

> “Here we show that muscarinic receptor antagonism at the hypoglossal motor pool prevents the inhibition of genioglossus activity throughout REM sleep; likewise, with G-protein-coupled inwardly rectifying potassium (GIRK) channel blockade.”
> “This mechanism is the major cause of REM sleep inhibition at a pharyngeal motor pool critical for effective breathing.”

Source: [Grace et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23220910/)

<a id="topic-2.2.1.4-8"></a>

### Pharyngeal dilator muscle control: genioglossus motor unit activity during REM sleep in humans

> “Overall these data show diminished genioglossus activity during REM (particularly phasic REM) as evidenced by fewer SMUs being active, reduced discharge frequencies, and shorter firing durations.”
> “Neither the source of this cholinergic input nor the nature of interactions between cholinergic, noradrenergic, and other excitatory neurochemicals is understood.”

Source: [McSharry et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3920322/)

<a id="topic-2.2.1.4-9"></a>

### Pharyngeal dilator muscle control: hypoglossal motor nucleus mechanisms targeted by AD109 (review; one author is an Apnimed employee)

> “While anatomical vulnerability contributes to airway instability, a key determinant of OSA pathophysiology is the sleep-related reduction in upper airway neuromuscular activity that occurs at the wake–sleep transition.”
> “Nonanatomical causes contribute to OSA in approximately 70% of patients.”
> “This endogenous noradrenergic excitation at the HMN is present in wakefulness, reduced in non-REM (NREM) sleep, and further reduced in REM sleep.”
> “Upper airway dilator muscle activity decreases during sleep due to withdrawal of excitatory drive, including noradrenergic input, in rapid eye movement (REM) and non-REM (NREM) sleep, and recruitment of inhibitory muscarinic–GIRK (G-protein–coupled inwardly rectifying potassium) mechanisms in REM sleep at upper airway motor nuclei.”
> “AD109 combines norepinephrine reuptake inhibition (atomoxetine) to restore excitatory drive and antimuscarinic activity (aroxybutynin) to reduce inhibition, thereby stabilizing upper airway muscle tone and improving airway patency.”
> “R.L.H.’s laboratory received an unrestricted grant in September 2024 from Apnimed, Inc. to support future research in obstructive sleep apnea (OSA) pharmacotherapy.”
> “L.T.-M. is an Apnimed employee and is co-inventor of intellectual property for pharmacological therapy of OSA via the Brigham and Women’s Hospital.”

Source: [Horner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316936/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
